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Background: Controlled human malaria infection (CHMI) studies are a vital tool to
accelerate vaccine and drug development. As CHMI trials are performed in a controlled
environment, they allow unprecedented, detailed evaluation of parasite growth dynamics
(PGD) and immunological responses. However, CHMI studies have not been routinely
performed in malaria-endemic countries or used to investigate mechanisms of naturally-
acquired immunity (NAI) to Plasmodium falciparum.
Methods: We conducted an open-label, randomized CHMI pilot-study using aseptic,
cryopreserved P. falciparum sporozoites (PfSPZ Challenge) to evaluate safety, infectivity
and PGD in Kenyan adults with low to moderate prior exposure to P. falciparum (Pan African
Clinical Trial Registry: PACTR20121100033272).
Results: All participants developed blood-stage infection confirmed by quantitative
polymerase chain reaction (qPCR). However one volunteer (110) remained asymptomatic
and blood-film negative until day 21 post-injection of PfSPZ Challenge. This volunteer had
a reduced parasite multiplication rate (PMR) (1.3) in comparison to the other 27 volunteers
(median 11.1). A significant correlation was seen between PMR and screening anti-schizont
Enzyme Linked Immunosorbent Assays (ELISA) OD (p = 0.044, R = −0.384) but not when
volunteer 110 was excluded from the analysis (p = 0.112, R = −0.313).
Conclusions: PfSPZ Challenge is safe and infectious in malaria-endemic populations and
could be used to assess the efficacy of malaria vaccines and drugs in African populations.
Whilst our findings are limited by sample size, our pilot study has demonstrated for the
first time that NAI may impact on PMR post-CHMI in a detectable fashion, an important
finding that should be evaluated in further CHMI studies.
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INTRODUCTION
Controlled human malaria infection (CHMI) studies, where
healthy volunteers are infected with P. falciparum to assess the
efficacy of novel malaria vaccines and drugs, have become a vital
tool to accelerate vaccine and drug development (Chulay et al.,
1986; Mccarthy et al., 2011; Sauerwein et al., 2011; Roestenberg
et al., 2012a). As CHMI trials are carried out in a controlled
environment, they allow unprecedented detailed evaluation of
parasite growth dynamics (PGD) and immunological responses
to infection. However, to date they have not been used to help
understand the mechanisms and impact of naturally-acquired
immunity (NAI) to P. falciparum infection (Sheehy et al., 2013a).
www.frontiersin.org December 2014 | Volume 5 | Article 686 | 1
Hodgson et al. Evaluating CHMI in Kenyan adults
Repeated infection with P. falciparum leads to the development
of NAI, conferring protection in adults against severe disease
(White et al., 2014). Whilst antibodies against blood-stage anti-
gens are thought to be key mediators of natural immunity, the
exact mechanism(s) of protection in humans in vivo remain
unknown (Langhorne et al., 2008). Evidence from a comparison
of parasite multiplication rates (PMR) showed a 7-fold reduc-
tion in PMRs between malaria-naïve volunteers in CHMI studies
in Oxford vs. Gambian adults with NAI, suggesting that NAI
impacts on PMR in a detectable fashion that could be quantified
in a modern CHMI study (Douglas et al., 2011). It should there-
fore be possible to correlate prior exposure to malaria (a generally
accepted surrogate of natural immunity) (Langhorne et al., 2008)
with PMR following CHMI, and in turn seek to examine poten-
tial correlates of NAI. As well as identifying important antigenic
targets, this could allow validation of proposed in vitro mea-
sures of NAI, including growth inhibition antibody activity (GIA)
and antibody-dependant cellular assays (Tippett et al., 2007; Joos
et al., 2010; Duncan et al., 2012; Hill et al., 2012; Sheehy et al.,
2013a).
Though commonly performed in malaria-naïve populations
(Sauerwein et al., 2011), CHMI trials have rarely been conducted
in malaria endemic regions (Sheehy et al., 2013a). In 1957 in
Lagos, 22 adults with prior exposure to malaria were challenged
with “an intravenous injection of blood heavily parasitized with P.
falciparum” (Bruce-Chwatt, 1963a,b). Whilst infection was suc-
cessfully induced in 11 volunteers, examination of parasite load
measured by blood film fromday of injection of parasites for up to
8 weeks clearly showed individuals controlling and in some cases,
clearing parasitemia. In a study published in 1954 conducted
in Nairobi 30 adults were challenged with P. falciparum malaria
(Allison, 1954). The study clearly demonstrated a protective effect
of sickle cell trait in the 15 individuals with this condition. A
further study involving the inoculation of semi-immune individ-
uals with P. falciparum was also conducted in Liberia in the 1960s
(Bray et al., 1962). However, in the time since these studies, these
investigations have not been repeated.
To date, the majority of recent CHMI studies have been
undertaken by administration of sporozoites by mosquito-bite
(Sauerwein et al., 2011; Sheehy et al., 2013a). A major obstacle
to performing such studies in malaria endemic regions has been
the lack of access to appropriate insectary facilities (Sheehy et al.,
2013a). The development of aseptic, cryopreserved P. falciparum
sporozoites (NF54 strain) for injection (PfSPZ Challenge) by the
biotechnology company Sanaria Inc., has helped overcome this
problem (Roestenberg et al., 2013; Sheehy et al., 2013b).
Three studies using PfSPZ Challenge have been published to
date; two performed in malaria-naïve European volunteers and
one in Tanzanian volunteers (Roestenberg et al., 2013; Sheehy
et al., 2013b; Shekalaghe et al., 2014). These studies examined
the effect of dose, route and volume of administration of PfSPZ
Challenge on infectivity, in order to identify a protocol that reli-
ably infects 100% of volunteers. Whilst intradermal (ID) admin-
istration was more efficient than intramuscular (IM) in terms of
infectivity, 25,000 sporozoites administered IM rather than ID
was the only regimen found to infect 100% of volunteers (Sheehy
et al., 2013b).
We sought to establish the sporozoite CHMI model in a
Kenyan setting using PfSPZ Challenge, with the aim of increasing
the international capacity for efficacy testing of malaria vac-
cines and drugs and allowing earlier assessment of efficacy in a
population for which vaccines are being developed. We enrolled
28 adults with varying degrees of prior exposure to malaria in
order to include an evaluation of the effect of NAI on PGD
post CHMI.
MATERIALS AND METHODS (SEE SUPPLEMENTARY
INFORMATION)
STUDY DESIGN
The study was an open label, randomized pilot study with blinded
laboratory outcome assessment, evaluating PfSPZ Challenge
administered to 28 individuals with varying degrees of prior
exposure to P. falciparum (Figure 1). To ensure infection and
detectable parasitemia post-CHMI, a dose of 125,000 sporozoites
IM was chosen for the main study cohort (n = 20). Since the
maximum dose of PfSPZ Challenge administered IM to humans
at the time of study design was 25,000 IM (Sheehy et al., 2013b),
two additional small cohorts receiving lower doses of 25,000 (n =
4) and 75,000 (n = 4) sporozoites IM were included in the study
design to allow assessment of safety prior to administration of
125,000 sporozoites IM.
The study was conducted at the KEMRI Centre for Clinical
Research, Nairobi, Kenya. Nairobi was chosen as the study site
due to the lack of natural transmission of P. falciparum in the city,
the ease of access to tertiary health care and the large number of
educated adults drawn from all parts of Kenya, which would help
ensure heterogeneity in prior exposure to P. falciparum in study
participants. The study was conducted according to the princi-
ples of the Declaration of Helsinki and in accordance with Good
Clinical Practice (GCP).
SENSITIZATION AND RECRUITMENT
As the first CHMI study to take place in Kenya, the study was
discussed prior to submission, in detail with the KEMRI Ethics
Review Committee (ERC) and the Kenyan Ministry of Health.
Following ethical and regulatory approval of the study, meetings
were held with senior managers of local universities to pro-
vide information regarding the study and gain permission to
hold sensitization meetings with the students at their institu-
tions. Interested individuals at these meetings were then invited
to screening appointments.
All participants were required to provide evidence of comple-
tion of secondary education (typically completed at age 16–18
years) and answer all questions on a questionnaire assessing com-
prehension of the study correctly prior to giving written consent.
All volunteers received the study information at least 24 h in
advance of the screening appointment.
SCREENING
Key inclusion criteria included healthy males and non-pregnant
females aged 18–40 years and agreement to stay as an in-
patient from the day before administration of PfSPZ Challenge
until completion of anti-malarial treatment. Key exclusion cri-
teria included quantitative polymerase chain reaction (qPCR)
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FIGURE 1 | Study design and volunteer recruitment. 118 participants were excluded following screening (refer to Figure S1 for details). In each group, the
total dose of sporozoites was split between two injection sites and administered as two 50μL injections, one in each deltoid.
positivity for P. falciparum at screening, hemoglobinopathies
likely to impact on study results and prior receipt of an investi-
gational malaria vaccine (see Supplementary Information for full
list of inclusion and exclusion criteria).
At screening, in addition to a full medical history, exami-
nation, urinalysis, and pregnancy test in females, safety blood
tests (including complete blood count, hamoglobinopathy screen,
electrolytes, liver function tests and assays for HIV, hepati-
tis B, hepatitis C) and an electrocardiogram were performed
for each volunteer to identify and exclude any individuals
with baseline abnormalities (Nieman et al., 2009; Van Meer
et al., 2014). Highly sensitive qPCR for P. falciparum was per-
formed on screening blood samples to identify and exclude any
individuals with asymptomatic parasitemia (see Supplementary
Information). Volunteers were asked not to leave Nairobi between
screening and enrolment in order to prevent acquisition of
community-acquired P. falciparum infection prior to adminis-
tration of PfSPZ Challenge. Volunteers positive for P. falciparum
by qPCR at screening were treated with a therapeutic course of
Co-Artem® as per national guidelines and excluded from partic-
ipation. Volunteers with clinically significant illness at screening
were excluded and referred for appropriate management as per
national guidelines.
GROUP ALLOCATION
Volunteers’ prior exposure to P. falciparum was assessed using
anti-schizont and anti-merozoite surface protein 2 (MSP2)
Enzyme Linked Immunosorbent Assays (ELISA) at a serum
dilution of 1:1000 as previously described (see Supplementary
Information) (Osier et al., 2008). Given the lack of a known
assay to reliably assess NAI to P. falciparum (Langhorne et al.,
2008), these two antigens were chosen for screening purposes
on the basis of their published positive association with prior
exposure to P. falciparum (Marsh et al., 1989; Drakeley et al.,
2005; Polley et al., 2006; Mccallum et al., 2008; Osier et al.,
2008).
Absolute ELISA OD results to these two antigens for screening
samples were compared to negative controls (non-exposed UK
sera; n = 30) and the cut off for seropositivity determined as the
mean absolute ELISA OD plus 3 standard deviations of the nega-
tive controls (0.23 and 0.07 for reactivity against schizont extract
andMSP2 respectively). Individuals were then classified as having
“minimal” prior exposure to malaria (MinExp) if both anti-
schizont and anti-merozoite ELISAs were negative, and as having
“definite” prior exposure to malaria (DefExp) if the anti-schizont
and/or the anti-MSP2 ELISA was positive.
After exclusion of volunteers not meeting the criteria for
MinExp or DefExp, 28 volunteers were identified as potential
participants in the study; 14 with the highest positive anti-
schizont ODs (DefExp) and 14 with negative anti-schizont and
anti-MSP2 ODs (MinExp). Given the high number of partici-
pants meeting exclusion criteria (Figure S1), a number of these
“first choice” DefExp individuals were unable to participate in
the study. Subsequent DefExp volunteers were selected from those
with the highest positive anti-schizont ELISA ODs in descend-
ing order (Absolute ELISA OD range 0.25–0.97). Once the final
28 volunteers were identified they were randomly allocated to
appropriate groups (Figure 1).
ADVERSE EVENTS (AEs) AND CRITERIA FOR TREATMENT WITH
ANTI-MALARIAL THERAPY
AEs were solicited daily from injection of PfSPZ Challenge,
graded for severity (according to the criteria in Tables S1,
S2) and classified as definitely, probably, possibly or unlikely
related to (a) PfSPZ Challenge injection, (b) malaria infec-
tion, or (c) anti-malarial therapy. Anti-malarial therapy was
commenced in any one of the following circumstances; posi-
tive blood-film on microscopy; symptoms highly consistent with
P. falciparum infection in the opinion of clinical investigators
(such as fever, rigors or severe symptomatology); reaching day
21 post-injection of PfSPZ Challenge (d+C21) without blood-
film positivity or symptomatology; or on withdrawal from study
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prior to initiation of anti-malarial therapy. A positive blood-
film on microscopy was defined as at least two morphologi-
cally normal, “unambiguous” malaria parasites seen by two or
more experienced microscopists blinded to each other’s find-
ings. A third microscopist reconciled any discrepant readings
(see Supplementary Information). Blood samples were processed
in real time for qPCR for P. falciparum, however, DNA extrac-
tion and qPCR were performed at a later date and so the
qPCR data did not contribute to decisions to start anti-malarial
therapy.
PARASITE GROWTH MODELING
Sampling for qPCR was performed 1–2 times a day and qPCR
conducted as previously described (Sheehy et al., 2012). Results
weremodeled using simple linear regression (Douglas et al., 2013)
to estimate two key measures; liver to blood parasite inoculum
(LBI) and PMR (see Supplementary Information). LBI is a quan-
titation of the total number of parasites released from the liver
and a useful indicator of the infectious parasite load in the liver. In
sporozoite CHMI studies administered by 5 infectious mosquito-
bites, LBI, estimated using the geometric mean of parasitemia
in the blood after the first cycle of asexual replication, ranged
between 240,000 and 2,835,000 parasites, depending on CHMI
center (Roestenberg et al., 2012b). PMR is the fold change in
number of parasites in the blood over one lifecycle (48 h). P. fal-
ciparum schizonts usually contain approximately 20 merozoites
(White et al., 2014). If all of these successfully invade a different
red blood cell, the PMR would be 20. In CHMI studies including
individuals with no NAI to malaria, PMR has been reported to
range between 12 and 15 (Sheehy et al., 2012; Roestenberg et al.,
2012b).
STATISTICAL ANALYSIS
The study was designed to assess proof of concept and group sizes
were pragmatic rather than based on a formal sample size cal-
culation for any one defined endpoint; statistical analyses were
therefore primarily descriptive in nature with between group tests
used sparingly and results interpreted with caution. qPCR results
were compared between groups using the Mann–Whitney U-test
(or Kruskal–Wallis test when comparing more than 2 groups).
Time to treatment was presented using Kaplan–Meier survival
curves and between group comparisons made using the log-rank
test. Correlations were assessed using Spearman’s rank correlation
coefficient. Data were analyzed using GraphPad Prism version
5.03 for Windows (GraphPad Software Inc., USA) and Stata
version 11 (StataCorp, Texas).
RESULTS
STUDY PARTICIPANTS AND MALARIA DIAGNOSIS
Recruitment took place in March—April 2013 when 146 vol-
unteers were screened. Twenty-eight healthy adults (11 female
and 17 male) underwent CHMI in May 2013 (Figure 1). The
mean age of participants was 25 years (range 19–31 years) (Table
S3). The distribution of anti-schizont and anti-MSP2 antibody
OD readings of enrolled DefExp and MinExp participants at
screening is shown in Figure 2. A significant correlation was
seen between results from these two assays (p ≤ 0.0001, R =
FIGURE 2 | Antibody ELISA absolute OD readings measured at
screening. (A) Anti-schizont. (B) Anti-MSP2. Serum diluted 1:1000.
Negative controls = OD readings from UK malaria naïve adults (n = 30).
Positive controls = OD readings from hyperimmune Kenyan adults living in
malaria endemic regions (n = 6). Minimal exposure = subjects enrolled in
groups 1, 3, and 5 (n = 14). Definite exposure = subjects enrolled in groups
2, 4, and 6 (n = 14). Screened subjects = all volunteers that had blood
drawn at screening (n = 145). A significant difference was seen between
minimally and definitely exposed volunteers for both antigens
(Anti-schizont = p ≤ 0.0001; Anti-MSP2 = p = 0.006; Mann–Whitney test).
Median values represented by lines through each dataset.
0.5807). All participants received injection of PfSPZ Challenge
and completed the study as scheduled.
All volunteers were diagnosed with malaria [see Table S5 for
criteria for treatment and Table S6 for time to diagnosis (TTD)
and parasitemia at diagnosis] with the exception of one volunteer
in Group 2 (Volunteer 110), who was asymptomatic and blood
film negative at all time-points, despite blood-stage infection con-
firmed by qPCR. This volunteer had the highest anti-schizont and
MSP2 antibody OD readings at screening of all enrolled partic-
ipants (Figure 2). There was no apparent relationship between
dose of PfSPZ Challenge and TTD inMinExp volunteers (Median
12.6, 11.8, and 12.0 days for Groups 1, 3, and 5 respectively; p =
0.571 log rank test; Figure S2A) or DefExp volunteers (Median
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FIGURE 3 | Analysis of adverse events associated with clinical malaria.
(A) Comparison of the total number of AEs (excluding laboratory AEs)
deemed possibly, probably or definitely related to clinical malaria infection in
individuals diagnosed with malaria in Groups 1, 3, and 5 (Minimally exposed;
mean = 7.1, median = 6.0) and Groups 2, 4, and 6 (Definitely exposed; mean
= 6.3, median = 7.0) (Mann–Whitney test; p = 0.746). The median value is
represented by a straight line through each plot. (B) Comparison of the
duration of symptoms deemed possibly, probably or definitely related to
clinical malaria infection in individuals diagnosed with malaria in Groups 1, 3,
and 5 (Minimally exposed; mean = 11.8, median = 6.5) and Groups 2, 4, and
6 (Definitely exposed; mean = 6.3, median = 3.0) (Mann–Whitney test;
p = 0.142). The median value is represented by a straight line through each
plot. (C) Comparison of maximum severity of any symptom of clinical malaria
infection between individuals diagnosed with malaria in in Groups 1, 3, and 5
(Minimally exposed) and Groups 2, 4, and 6 (Definitely exposed). (D)
Laboratory AEs after CHMI deemed possibly, probably or definitely related to
clinical P. falciparum infection. For “any laboratory abnormality” only the
highest intensity AE per subject is counted.
16.4, 13.3, and 11.9 days for Groups 2, 4 and 6 respectively; p =
0.332 log rank test; Figure S2B); no significant difference in TTD
between Group 1 and six malaria naïve volunteers who received
25,000 sporozoites IM in a previous UK study (Median TTD
12.5 vs. 13.0 days. p = 0.487 log rank test; Figure S2C) (Sheehy
et al., 2013b) and no significant difference in TTD for MinExp
and DefExp volunteers (Median 12.2 and 12.1 days respectively;
p = 0.171 log rank test; Figure S3D).
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FIGURE 4 | qPCR-measured parasite density for each individual
subject. Y-axis = parasites/mL. X-axis = days post challenge (calculated
from hours post challenge). Red line = mean parasite density over time for
all subjects.
PfSPZ CHALLENGE REACTOGENICITY
PfSPZ Challenge was well tolerated with only one AE deemed
possibly, probably or definitely related to injection of sporozoites
noted; mild injection site pain in a participant in Group 5 lasting
for the day of injection only.
PfSPZ INDUCED CLINICAL PLASMODIUM FALCIPARUM INFECTION
(TABLES S7, S8)
No unexpected or serious AEs occurred. Twenty-two of the
27 participants diagnosed with malaria were asymptomatic at
the time of diagnosis (81%; MinExp n = 10, DefExp n = 12),
however all developed at least one symptom or sign consis-
tent with malaria infection before treatment was completed
(Figure 3A). The total duration of symptoms in participants
with symptomatic malaria infection ranged from 1 to 26 days
(median 4 days) (Figure 3B). Particularly long-lasting AEs (>20
days) occurred in 8 participants (MinExp n = 6, DefExp n =
2) and included headache (n = 5), anorexia (n = 4), low back
pain (n = 2), fatigue (n = 2), and arthralgia (n = 1). There was
no difference in the number, duration, or severity of symp-
toms of malaria between MinExp and DefExp participants
(Figures 3A–C). Seventeen out of 27 participants diagnosed with
P. falciparum (63%) experienced at least one AE post CHMI that
was severe in intensity (Figure 3C). Three volunteers diagnosed
with malaria (11%) had a fever (>37.5◦C) prior to diagno-
sis (MinExp n = 2, DefExp n = 1) and 17 participants (63%)
developed a fever following treatment (MinExp n = 8, DefExp
n = 9). Safety bloods taken 9 days after initiation of CHMI
(dC+9), dC+35, dC+90 and within 24 h of diagnosis demon-
strated transient laboratory abnormalities at frequencies and
severities expected following P. falciparum infection in CHMI
studies (Figure 3D) (Epstein et al., 2007; Sheehy et al., 2012).
PARASITEMIA MEASURED BY qPCR
Figure 4 and Figure S3 plot the qPCR results over time for each
individual in the trial. There was no significant difference in
PMR or LBI between groups (p = 0.251 and p = 0.557 respec-
tively; Kruskall–Wallis test Figures 5A,B) or between MinExp
and DefExp participants (p = 0.206 and p = 0.597 respectively;
Mann–Whitney test Figures 5C,D). A significant correlation was
seen between anti-schizont antibody OD at screening and PMR
(Spearman rank = -pearman p = 0.044) but not LBI (Spearman
rank = −0.124, p = 0.529) (Figures 5E,F). No significant cor-
relation was seen between anti-schizont OD and PMR when
volunteer 110 was excluded from the analysis (p = 0.112, R =
0.313). In contrast to previous published data, no relationship
was seen between LBI and PMR (Spearman rank = −0.176, p =
0.371) (Douglas et al., 2013). The qPCR data for Volunteer 110
are shown in Figure 6. Volunteer 110 had a notably reduced PMR
(1.3) in comparison to the other 27 volunteers (median 11.1).
Importantly, Volunteer 110 was qPCR positive on dC+7 (mean
18 p/mL; triplicate readings; 14, 38, and 0 p/mL, positivity at this
time-point confirmed using a second PCRmethod, Murphy et al.,
2012) and then subsequently qPCR negative until dC+19, sug-
gesting control of blood-stage parasite growth rather than an
extremely low or undetectable LBI. Moreover, the LBI in this
volunteer was mid-range, in comparison to all other challenges
(Figures 5B,D).
We compared MSP2 genotypes of the blood-stage infections
using the Agilent Bioanalyzer to examine the qPCR products fol-
lowing amplification of the MSP2 gene (Liljander et al., 2009).
The fragment sizes were similar to within 10 base pairs (within
the error of the method) and therefore all infections were
clonal (NF54) and assumed to result from injection with PfSPZ
Challenge rather than being naturally acquired.
DISCUSSION
The primary aim of our pilot study was to establish the parame-
ters for safely and practically performing CHMI studies in Kenya.
Given the unknown effects of prior exposure to malaria on
CHMI, we sought to include individuals with both MinExp and
DefExp to P. falciparum and therefore, presumed varying lev-
els of NAI. Our study has shown that the CHMI model using
PfSPZ Challenge is safe in African adults with no significant dif-
ferences in AEs seen between DefExp and MinExp volunteers.
Importantly, we observed a similar safety profile to that reported
in malaria-naïve subjects who underwent CHMI, with the excep-
tion that Kenyan participants experienced AEs of a notably longer
duration than malaria-naïve volunteers, the reason for which is
unclear (Roestenberg et al., 2012b; Sheehy et al., 2012, 2013b).
Despite screening nearly 150 volunteers, only a third were eli-
gible to participate in the study (Figure S1). As the first CHMI
study undertaken in Kenya, the exclusion criteria were extensive.
Issues likely to be pertinent to other trials in Africa, such as the
high degree of previously undiagnosed co-morbidities, asymp-
tomatic qPCR positivity and hemoglobinopathies, restricted
recruitment. For future Kenyan CHMI studies we anticipate
screening large numbers of volunteers to identify a sufficient
number of healthy, eligible adults.
Of our screened cohort, only 5 individuals had anti-schizont
OD readings of the same order as “hyperimmune” con-
trols (Figure 2). Due to a high degree of previously undi-
agnosed co-morbidities in these 5 individuals, only one of
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FIGURE 5 | Modeling of qPCR-measured parasite density to calculate
parasite multiplication rates and liver-to-blood inocula. (A) Dot plot of
PMR according to Group (p = 0.251; Kruskal–Wallis test). (B) Dot plot of LBI
according to Group (p = 0.547; Kruskal–Wallis test). (C) PMR according to
prior exposure to malaria (p = 0.206; Mann–Whitney test). The median value
is represented by a straight line through each plot (D) LBI according to prior
exposure to malaria (p = 0.700; Mann–Whitney test). Median value is
represented by a straight line through each plot. (E) Relationship between
PMR and anti-schizont ELISA OD measured at screening (Spearman rank
= −0.384; p = 0.044). (F) Relationship between LBI and anti-schizont ELISA
OD measured at screening (Spearman rank = −0.123; p = 0.534). In all
graphs Volunteer 110’s data points are represented as open points. PMR =
parasite multiplication rate (fold change in parasites/mL over 48 h). LBI =
Liver-to-blood Inocula (total number of parasites released from liver).
these volunteers was subsequently eligible to participate in
the study. In practice therefore, our study included subjects
with varying but probably low to moderate prior exposure
to P. falciparum. Nevertheless, there was no overlap between
the anti-schizont reactivities of those with definite vs. mini-
mal exposure. If future Kenyan CHMI studies seek to enroll
“hyperimmune” adults, it will be important to either screen
a considerably larger sample of individuals or to do targeted
screening.
However, despite the lack of “hyperimmune” individuals in
our study, we still have preliminary evidence of the potential of
the CHMImodel to detect differences in individuals’ NAI to P. fal-
ciparum. This is demonstrated first by the relationship between
the anti-schizont OD reading at screening and PMR post-CHMI
(Figure 5E), and second by the case of the individual with the
highest anti-schizont ELISAOD at screening (Volunteer 110) who
remained asymptomatic and blood-film negative despite qPCR
confirmed P. falciparum infection. Comparison of PMRs from
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FIGURE 6 | qPCR results post-challenge for volunteer 110, group 2.
Long dashed line = lower limit of detection (i.e., a probability of >50%
of ≥1 positive result among three replicate PCR reactions) for qPCR assay
(5 parasites/mL). Short dashed line = lower limit of quantification (defined
as %CV < 20%) for qPCR assay (20 parasites/mL).
our study with the only other published measurement of PMR
in the context of NAI (Douglas et al., 2011) showed that this
volunteer had a similar PMR to those measured in Gambian
adults participating as controls in a malaria vaccine field efficacy
study (Imoukhuede et al., 2007; Douglas et al., 2011). However,
it should be noted these latter adult volunteers had presum-
ably been infected multiple times before with local circulating
strains against which they had developed effective immunity, in
contrast to our study which used the historical laboratory ref-
erence strain NF54, which, although of African origin, may not
completely reflect the strains against which our volunteers were
naturally exposed in the past. Other volunteers in our study
appeared to have PMRs broadly similar to malaria naïve controls
post CHMI administered by mosquito bite (Roestenberg et al.,
2012b; Sheehy et al., 2012; Douglas et al., 2013). Nevertheless,
key methodological differences in qPCR analysis and study design
(including “drug clearance” before qPCR sampling) between
these studies and limited other trials reporting vaccine-induced
reduction in parasite growth post-CHMI (Thompson et al.,
2008; Spring et al., 2009), make comparison of PMRs across
these various settings largely difficult to interpret (Sheehy et al.,
2013a).
Examination of Volunteer 110’s qPCR data over time show
a positive qPCR result on dC+7.0 followed by a run of mostly
negative results, until dC+19.0 when all subsequent qPCR results
became positive. Whilst it is not possible to draw definite conclu-
sions regarding themechanism by which this volunteer controlled
parasite growth, this pattern of qPCR positivity could suggest
the first wave of merozoites released from the liver invaded red
blood cells and thus were detectable at dC+7.0 post-CHMI and
not completely controlled by anti-merozoite immunity. The sub-
sequent run of negative qPCR results would be consistent with
control of parasite growth mediated by existing anti-PfEMP1 or
anti-infected red blood cell (iRBC) antibodies, followed by loss
of control of parasite growth. This could occur following a var
gene switch, leading to a change in variant surface antigen to
one that is not recognized by existing antibodies (Peters et al.,
2002; Warimwe et al., 2009). Further work will now assess assays
of anti-merozoite immunity and var gene expression during the
blood-stage of infection in Volunteer 110 to evaluate this hypoth-
esis. Alternatively, there is a possibility that the late increase in
qPCR seen in this volunteer represented gametocytaemia. Given
that no asexual parasites were seen at any time-point on blood-
film we think this unlikely, however future trials could consider
performing gametocyte-specific qPCR in such scenarios to test for
this possibility (Wampfler et al., 2013).
Our study importantly confirms the infectivity of PfSPZ
Challenge in malaria exposed individuals, supporting the future
use of PfSPZ Challenge in malaria endemic regions to test vac-
cines and anti-malaria drugs. In contrast to previous clinical data
(Sheehy et al., 2013b), our study showed no significant increase in
infectivity (measured by LBI, TTD, or proportion of participants
infected) with increasing dose of PfSPZ Challenge IM, suggesting
25,000 sporozoites may be a sufficient dose to ensure infec-
tion when administered IM. Recent trials using PfSPZ Challenge
administered intravenously (IV) suggest this route of administra-
tion can reliably ensure successful infection in CHMI trials with
lower doses of sporozoites than those required when administered
by other routes (Hoffman, Pers. Commun.). Since IV administra-
tion can reduce the variation in LBI between volunteers and allow
an infectious dose more closely approximating that seen in the
field, this route of injection of PfSPZ Challenge may be the way
forward for future CHMI studies aiming to examine the dynamics
of NAI.
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Figure S1 | Primary reasons for exclusion of volunteers. Of note, some
individuals met multiple exclusion criteria. This figure illustrates the
primary reason for exclusion for each volunteer. HIV, human
immunodeficiency virus; ECG, electrocardiogram; PCR, quantitative
polymerase chain reaction for P. falciparum; ALT, Alanine transaminase;
Homo α thal, Homozygous α thalassemia; Hetero α thal, Heterozygous α
thalassemia; βHCG, β Human Chorionic Gonadotropin.
Figure S2 | Kaplan–Meier analysis of Time to Diagnosis. Time to diagnosis
(TTD) calculated in hours and converted to days from injection of PfSPZ
Challenge and meeting end-point criteria. (A) Effect of dose of PfSPZ
Challenge on TTD in minimally exposed participants. Median pre-patent
period = 12.6 days for Group 1, 11.8 days for Group 3 and 12.0 days for
Group 5 (Log-rank test; p = 0.571). (B) Effect of dose of PfSPZ Challenge
on TTD in Definitely exposed participants. Median pre-patent period =
16.4 days for Group 2, 13.3 days for Group 4 and 11.9 days for Group 6. (C)
Comparison of pre-patent period between malaria naïve UK volunteers
(n = 6) (Sheehy et al., 2013b) and Kenyan minimally exposed volunteers
(Group 1; n = 2) receiving PfSPZ Challenge 25,000 IM. Median pre-patent
period = 12.9 days for UK volunteers and 12.6 days for Group 1 (Log-rank
test; p = 0.487). (D) Effect of prior exposure to P. falciparum on TTD.
Minimally exposed = Groups 1, 3, and 5. Definitely exposed = Groups 2,
4, and 6. Median pre-patient period = 12.2 days for Minimally exposed
and 12.1 days for Definitely exposed (Log-rank test; p = 0.171).
Figure S3 | qPCR-measured parasite density over time for each individual
subject. Y-axis = Parasites/mL measured by qPCR. X-axis = days
post-injection of PfSPZ Challenge. Black subtitles indicate participant
identification numbers.
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